Valuation: Agenus Inc.

Market Cap 384M 337M 319M 290M 544M 36.85B 547M 3.81B 1.48B 18.83B 1.44B 1.41B 60.5B P/E 2026 *
34.6x
P/E 2027 * -18x
Enterprise Value 384M 337M 319M 290M 544M 36.85B 547M 3.81B 1.48B 18.83B 1.44B 1.41B 60.5B EV / Sales 2026 *
3.07x
EV / Sales 2027 * 3.32x
Free-Float
93.76%
Yield 2026 *
-
Yield 2027 * -
1 day+0.47%
1 week+8.79%
Current month+12.22%
1 month+3.52%
3 months+181.85%
6 months+148.26%
Current year+171.97%
1 week 7.6
Extreme 7.6
8.82
1 month 6.66
Extreme 6.66
8.82
Current year 2.71
Extreme 2.71
8.85
1 year 2.71
Extreme 2.71
8.85
3 years 1.38
Extreme 1.38
23.4
5 years 1.38
Extreme 1.38
117.2
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 1994-03-30
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 2021-10-31
Director TitleAgeSince
Chairman 73 2010-11-03
Director/Board Member 68 2007-03-07
Director/Board Member 68 2006-12-06
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 Free

Chief Executive Officer

1,971,500 4.4054%
8/5/26 Free

Director

50,000 0.1117%
8/5/26 Free

Director

50,000 0.1117%
Change 5-day change 1-year change 3-year change Capi.($)
+0.47%+8.79%+116.20%-62.87% 384M
-0.14%+4.33%+9.00%+31.64% 47.97B
-1.69%+1.48%+50.57%+34.53% 44.5B
+2.56%+7.34%+366.69%+608.26% 43.93B
+0.24%+2.85%+10.67%+94.47% 41.03B
-0.62%-1.11%+4.65%+48.91% 29.85B
-0.28%+1.07%+24.58%+155.58% 17.27B
+3.37%+9.21%+8.32% - 15.34B
-0.46%+1.20%+26.90%+42.21% 15.3B
-2.21%-4.70% - - 14.82B
Average +0.12%+3.89%+68.62%+119.09% 27.04B
Weighted average by Cap. +0.11%+2.89%+79.73%+159.92%

Financials

2026 *2027 *
Net sales 125M 110M 104M 94.56M 177M 12B 178M 1.24B 481M 6.13B 470M 460M 19.7B 116M 102M 96.11M 87.58M 164M 11.11B 165M 1.15B 445M 5.68B 435M 426M 18.25B
Net income 39.4M 34.57M 32.65M 29.76M 55.7M 3.78B 56.1M 391M 151M 1.93B 148M 145M 6.2B -28.55M -25.05M -23.66M -21.56M -40.36M -2.74B -40.65M -283M -110M -1.4B -107M -105M -4.49B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.
Employees
81
Date Price Change Volume
26-09-25 US$8.540 +0.47% 672,403
26-09-24 US$8.500 +1.19% 636,609
26-09-23 US$8.400 -3.45% 610,167
26-09-22 US$8.700 +4.44% 994,136
26-09-21 US$8.330 +6.11% 1,299,720
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.540USD
Average target price
26.33USD
Spread / Average Target
+208.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock